Veoza Approved for Menopause Treatment
Veoza (fezolinetant) has been officially approved for use on the National Health Service (NHS) in England, providing a new treatment option for menopausal women suffering from hot flushes. This decision is expected to benefit around 500,000 women across the country, particularly those for whom hormone replacement therapy (HRT) is unsuitable.
Hot flushes affect approximately 70% of women going through menopause, significantly impacting their quality of life. Veoza is designed as a once-daily oral tablet that works by blocking nerve pathways in the brain responsible for triggering these uncomfortable symptoms, including night sweats.
Helen Knight, a representative from the National Institute for Health and Care Excellence (NICE), stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She emphasized that this approval will provide much-needed relief to women who cannot or do not wish to take HRT.
Dr. Sue Mann, a healthcare expert, echoed these sentiments, noting, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She added that Veoza represents another vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.
The NHS has set the list price for Veoza at £44.80 per 28-tablet pack. NICE has determined that fezolinetant is cost-effective and offers value for taxpayers, making it a viable option for those in need.
Historically, there have been few safe and effective treatment options available for menopausal hot flushes, leaving many women to cope with these symptoms without adequate support. The introduction of Veoza marks a significant advancement in addressing this long-standing issue.
As the healthcare community anticipates the rollout of Veoza, observers are hopeful that it will provide a much-needed alternative for women seeking relief from menopause-related symptoms. However, details remain unconfirmed regarding the exact timeline for availability and distribution across NHS facilities.
You may also like
